NEW OR RETURNING USERS: SIGN IN  |   UPDATE PROFILE  |   CME/CE TRACKER    



  

Ophthalmology

What's New in AMD Therapy
This CME/CE activity has reached its termination date and no longer
offers continuing education credit. Please note that expired CME/CE
activities may not contain the most up-to-date information available.

Click here to view our current activities in Ophthalmology.

What's New in Age-related Macular
Degeneration (AMD) Therapy
Free 1-hour CME/CE Webcast Featuring Expert Faculty

Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in Americans. With our population aging, the number of people with AMD is on the rise.

This activity is directed to formulary directors, medical directors, pharmacy directors, and case managers who care for patients with AMD.

CHAIR
Stuart H. Levine, MD, MHA
Assistant Clinical Professor/Internal Medicine
University of California, Los Angeles
David Geffen School of Medicine
Chief Medical Officer
Prospect Medical
Los Angeles, California
FACULTY
Victor H. Gonzales, MD
Medical Director
Valley Retina Institute, P.A.
McAllen, TX

Glenda S. Owens, RPH, MHA, CDM
Vice President
Pharmacy Services
Arcadian Health Plan
San Dimas, CA
GUEST FACULTY
Ivan J. Suñer, MD
Associate Professor of Ophthalmology
Duke University Medical Center
  (Duke Eye Center)
Chief of Ophthalmology Service
Durham Veterans Affairs Medical Center
Durham, NC
top

TARGET AUDIENCE
This CME/CE activity is designed for formulary directors, medical directors, pharmacy directors, and case managers who care for patients with AMD.

ACTIVITY GOAL
The goal of this CME/CE activity is to review treatment for patients with AMD.

LEARNING OBJECTIVES
  • Utilizing an understanding of AMD, initiate early diagnosis in at-risk patients to minimize their loss of vision.

  • Integrate knowledge of the efficacy and safety/toxicity of current and emerging anti-VEGF therapies into strategic therapy regimens for patients with AMD.

  • Upon assessing the implications of new targeted therapies, integrate anti-VEGF therapies into regimens to improve patient vision outcomes and satisfaction.
ACTIVITY AGENDA
Stuart H. Levine, MD, MHA: Overview
Victor H. Gonzales, MD: Clinical Overview of AMD
Glenda S. Owens, RPh, MHA, CDM: Health-Related Quality of Life and Health Economics Associated with AMD
Stuart H. Levine, MD, MHA: Implications for the Managed Care Community

Faculty: Q & A
top

CME INFORMATION

STATEMENT OF ACCREDITATION: PHYSICIANS
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CE INFORMATION

STATEMENT OF ACCREDITATION: NURSES
This activity has been approved by the American Association of Critical Care Nurses (AACN) for 1.0 contact hour. Provider #00012705.

STATEMENT OF ACCREDITATION: PHARMACISTS
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been planned and implemented in accordance with ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the live Q&A program is 052-000-06-019-L01, and to the on-demand program is 052-000-06-019-H01. Either number provides 1 contact hour (0.1 CEU).

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Victor H. Gonzales, MD, has received grants from Genentech, Inc, OSI Eyetech, and Ista; is a consultant for OSI Eyetech; is on the speakers bureau for Genentech, Inc; and is on the advisory boards for Genentech, Inc, and OSI Eyetech. Dr. Gonzalez has disclosed that he will not reference unlabeled/unapproved uses of drugs.

Stuart H. Levine, MD, MHA, is on the speakers bureau of Forest Pharmaceuticals, Inc, Sanofi Synthelabo Inc, Takeda Pharmaceuticals North America, Inc; and is on the advisory board for Boehringer Ingelheim Pharmaceuticals, Inc and Forest Pharmaceuticals, Inc. Dr. Levine has disclosed that he will reference the unlabeled or unapproved uses of bevacizumab.

Glenda S. Owens, RPh, MHA, CDM, has received consulting fees from Boehringer Ingelheim Pharmaceuticals Inc, Genentech, Inc, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation. In addition she is a shareholder of Genentech, Inc. Ms. Owens has disclosed that she will not reference unlabeled/unapproved uses of drugs.

Ivan J. Suñer, MD, has received grants from Genentech, Inc and Optos Plc; is a consultant for Bausch & Lomb, Inc, Genentech, Inc, Optos Plc, OSI Eyetech, and Pfizer Inc; is on the speakers bureau of Bausch & Lomb, Inc, Genentech, Inc, Optos Plc, OSI Eyetech, and Pfizer Inc; and has received consulting fees from Genentech, Inc, OSI Eyetech, and Pfizer Inc. Dr. Suner has disclosed that he will reference the unlabeled or unapproved use of bevacizamab.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Click here for TECHNICAL REQUIREMENTS

This independent CME activity is supported by an educational grant from
Genentech, Inc.
top

1771
 

 
Program Information

Faculty
Target Audience
Activity Goal
Learning Objectives
CME Information
Disclosure Information
Technical Requirements

By clicking below, I certify that I have read the accompanying CME/CE and disclosure information and am ready to continue to this activity.

Release Date: Sep. 5, 2006.

Termination Date: Sep. 5, 2007.

Estimated Time for Completion of this Activity: 1.0 hour.



Recommend this page
Recommend this to a colleague


This independent CME/CE activity is supported by an educational grant from Genentech, Inc.



ABOUT US CONTACT US CONTRACT DIRECTIONS PRIVACY POLICY RESOURCES
Copyright © 1997-2008, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988